All In Biotech

Free tool

FAERS Monitor: Zurzuvae

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217369 or its brand name (Zurzuvae, Zuranolone). Reports on generic versions are filed under their own applications.

Reports

1,940

Serious

306

16% of reports

Hospitalization

101

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • somnolence637
  • dizziness368
  • fatigue299
  • anxiety151
  • sedation150
  • feeling abnormal139
  • suicidal ideation112
  • tremor106
  • feeling drunk91
  • depression86
  • nausea79
  • memory impairment74
  • drug ineffective73
  • gait disturbance73
  • insomnia69

Reports by year received

View as table
YearReports
20231
2024379
2025753
2026807

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,219 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
feeling drunkSignal91134.4109.811,775
sedationSignal15062.453.58,968
somnolenceSignal63734.432.320,760
suicidal ideationSignal11213.311.11,263
dizzinessSignal3688.07.32,301
tremorSignal1066.95.8536
feeling abnormalSignal1396.35.4620
memory impairmentSignal745.84.7294
anxietySignal1515.84.9596
fatigueSignal2994.23.8743
gait disturbanceSignal734.13.3172
depressionSignal864.13.3201
insomniaSignal692.82.280
nausea791.10.90
drug ineffective730.60.520

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.